PepGen, Inc. (NASDAQ:PEPG) Receives $11.75 Average PT from Analysts

Shares of PepGen, Inc. (NASDAQ:PEPG) have been given an average rating of “Moderate Buy” by the five brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $11.75.

A number of analysts have recently commented on PEPG shares. Weiss Ratings reissued a “sell (d-)” rating on shares of PepGen in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of PepGen from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, HC Wainwright boosted their target price on shares of PepGen from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, November 13th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. RA Capital Management L.P. grew its stake in shares of PepGen by 87.7% in the 3rd quarter. RA Capital Management L.P. now owns 20,064,545 shares of the company’s stock valued at $92,698,000 after buying an additional 9,375,000 shares during the period. Viking Global Investors LP boosted its holdings in PepGen by 134.9% in the third quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock worth $16,089,000 after acquiring an additional 2,000,000 shares in the last quarter. Commodore Capital LP acquired a new stake in PepGen in the third quarter valued at approximately $10,891,000. Vivo Capital LLC acquired a new stake in PepGen in the third quarter valued at approximately $10,742,000. Finally, Laurion Capital Management LP increased its holdings in shares of PepGen by 133.4% during the third quarter. Laurion Capital Management LP now owns 1,892,156 shares of the company’s stock valued at $8,742,000 after acquiring an additional 1,081,395 shares in the last quarter. 58.01% of the stock is owned by institutional investors and hedge funds.

PepGen Stock Performance

NASDAQ:PEPG opened at $5.13 on Wednesday. PepGen has a 52 week low of $0.88 and a 52 week high of $7.80. The firm’s 50-day simple moving average is $5.76 and its 200 day simple moving average is $3.93. The firm has a market cap of $352.69 million, a price-to-earnings ratio of -1.82 and a beta of 1.91.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.11. Sell-side analysts anticipate that PepGen will post -2.73 EPS for the current year.

About PepGen

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).